Diagnosis and treatment of dorsalgia in outpatient practice

Dorsalgia − nonspecific back pain is the leader in the number of requests for medical help. Nonspecific musculoskeletal pain accounts for up to 80–90% of all pain syndromes. Back pain can be provoked by professional static-dynamic overloads, violations of the statics of the musculoskeletal system, exposure to cold and/or vibration, overweight, hereditary factors, etc. In outpatient practice, doctors often have to deal with various forms and clinical manifestations of dorsalgia. The leading role in the diagnosis is given to the physical examination of the patient. With the active collection of complaints and anamnesis, the doctor has the opportunity to identify the leading problem that prompted the patient to seek medical help, clarify the localization of the process, the time of occurrence and the sequence of symptoms, which allows you to fully imagine the picture of the disease and differentiate between simultaneously occurring nosologies. The identification of the affected structure, which is the root cause of musculoskeletal pain, does not affect the appointment of basic drug therapy, but it is absolutely necessary when conducting local injection therapy, as well as a number of non-drug treatment methods. Among the pharmacological drugs used to treat musculoskeletal pain, the priority remains for NSAIDs, the choice of which, first of all, is dictated by its safety. The favorable safety profile of Nimesil® (nimesulide) has been confirmed by numerous domestic and foreign studies. Nimesulide is registered in 50 countries for the treatment of pain syndromes, and is also used as an antipyretic and anti-inflammatory drug. According to the results of a study in the Russian Federation, Nimesil® (nimesulide) turned out to be the most frequently prescribed drug, which is due to its high effectiveness and ability to accumulate in therapeutic concentration in the focus of inflammation. In addition to pharmacotherapy, the treatment regimen for musculoskeletal pain should include, on a parity basis, non-drug treatment methods that allow correction of pathobiomechanical changes. If ignored, in many cases, drug anesthesia does not lead to the desired effect, which can contribute to the chronization of pain. The described clinical case illustrates the simultaneous course of two variants of dorsalgia in the patient, different in localization, clinical manifestations, severity and duration of the course.

1. Kukushkin ML. Back pain: targets for pathogenetic therapy. RMJ. 2011;19(30):1862–1866. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Boly_v_spine_misheni_dlya_patogeneticheskoy_terapii/.

2. Кукушкин МЛ, Табеева ГР, Подчуфарова ЕВ. Болевой синдром: патофизиология, клиника, лечение: клинические рекомендации. М.: ИМА-Пресс. 2014; 64 с.

3. Sadokha KA, Golovko AM, Varikash MS. Some aspects of secondary dorsalgia. Meditsinskie Novosti. 2019;(2):29–34. (In Russ.) Available at: https://www.mednovosti.by/journal.aspx?article=8597.

4. Merkulov YuA, Gamburg AM, Lezina DS, Fedorova AN, Onsin AA, Merkulova DM. Optimizing the diagnosis and treatment of dorsalgia in real-world clinical practice: the secondary endpoint of the DORISS multicenter observational study. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;123(2):73–82. (In Russ.) https://doi.org/10.17116/jnevro202312302173.

5. Klimycheva MB. An integrated approach to the treatment of vertebrogenic pain. Lechaschi Vrach. 2023;10(26):32–37. (In Russ.) https://doi.org/10.51793/OS.2023.26.10.005.

6. Barinov AN, Zhestikova MG. Modern methods of effective treatment of dorsalgia. Effective Pharmacotherapy. 2015;(13):38–47. (In Russ.) Available at: https://umedp.ru/articles/sovremennye_metody_effektivnoy_terapii_dorsalgiy.html?sphrase_id=81308

7. Kamchatnov PR, Abusueva BA, Khanmurzaeva SB. Choosing treatment tactics for a patient with dorsalgia. Nervous Diseases. 2020;(2):53–59. (In Russ.) https://doi.org/10.24411/2226-0757-2020-12180.

8. Kapustina NV, Khafizov NN, Piskunova LG. Complex management approach to lower back pain. RMJ. 2016;(20):1375–1378. (In Russ.) Available at: https://www.rmj.ru/articles/zabolevaniya_kostno_myshechnoy_sistemy/Osobennosti_kompleksnogo_podhoda_k_lecheniyu_pacientov_s_dorsalgiey.

9. Chugunov AV, Kamchatnov PR. The use of combined drugs for the treatment of patients with acute dorsalgia. RMJ. 2021;(5):50–54. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Primenenie_kombinirovannyh_lekarstvennyh_preparatov_dlya_lecheniya_pacientov_s_ostroy_dorsalgiey/.

10. Смелов ПА, Никитина СЮ, Агеева ЛИ, Александрова ГА, Голубев НА, Кириллова ГН и др. Здравоохранение в России 2021. М.; 2021. 173 с. Режим доступа: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2021.pdf.

11. Davydov OS. The prevalence of pain syndromes and their impact on quality of life in the world and Russia, according to the data of the global burden of disease study in the period 1990 to 2013.russian Journal of Pain. 2015;48(3-4):11–18. (In Russ.) Available at: https://painrussia.ru/russian-Journal-of-Pain/47%2015.pdf.

12. Manevich TM, Mkhitaryan EA, Naumov AV. Perspectives of targeted therapy for nonspecific back pain: a review of recent publications.russian Journal of Geriatric Medicine. 2021;(3):321–326. (In Russ.) https://doi.org/10.37586/2686-8636-3-2021-313-318.

13. Sadokha K.A., Golovko A.M. Back pain: epidemiology, clinical manifestations, and classification. Lechebnoe Delo. 2016;6(52):53–56. (In Russ.) Available at: https://lech-delo.by/wp-content/uploads/content_ld_6_52_2016.jpg.

14. Ryabokon IV, Akarachkova ES. Complex therapy of pain syndrome in dorsalgia. Therapy. 2016;3(7):32–39. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/33290.

15. Nasonov EL, Yakhno NN, Karateev AE, Alekseeva LI, Barinov AN, Barulin AE et al. General principles of treatment for musculoskeletal pain: Interdis ciplinary consensus. Rheumatology Science and Practice. 2016;54(3):247–265. (In Russ.) https://doi.org/10.14412/1995-4484-2016-247-265.

16. Devlikamova FI, Khaybullina DKh, Maximov YuN, Gubeyev BE. Cervicocranialgia: a multitude of reasons, but only one issue. RMJ. 2019;(9):4–10. (In Russ.) Available at: https://www.rmj.ru/articles/bolevoy_sindrom/Cervikokranialgiya_mnoghestvo_prichin_odna_problema/.

17. Dadasheva MN, Agafonov BV, Shevtsova NN. Neurological Issues and Principles for Pain Relief during Cervicobrachial Syndrome (Cervicobrachialgia). Effective Pharmacotherapy. 2015;(1):28–34. (In Russ.) Available at: https://umedp.ru/articles/nevrologicheskie_aspekty_i_printsipy_kupirovaniya_boli_pri_sheynoplechevom_sindrome_tservikobrakhial.html.

18. Sakovets TG, Khuzina GR, Barysheva EN. Specifics of therapy for back pain in patients with facet syndrome. Bulletin of Contemporary Clinical Medicine. 2021;14(5):74–80. (In Russ.) https://doi.org/10.20969/VSKM.2021.14(5).74-80.

19. Maksimov YuN, Khaibullina DKh, Mansurov DM. Differential diagnosis and treatment of neck pain. Meditsinskiy Sovet. 2022;16(2):52–62. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-2-52-62.

20. Driessen MT, Lin CW, van Tulder MW. Cost-effectiveness of conservative treatments for neck pain: a systematic review on economic evaluations. Eur Spine J. 2012;21(8):1441–1450. https://doi.org/10.1007/s00586-012-2272-5.

21. Maksimov YuN, Khaibullina DKh. Complex myofascial pain syndrome. Manual Therapy. 2023;2(90):54–61. (In Russ.) Available at: https://mtj.editorum.ru/ru/nauka/article/69955/view.

22. Irnich D, Behrens N, Molzen H, König A, Gleditsch J, Krauss M et al. Randomised trial of acupuncture compared with conventional massage and “sham” laser acupuncture for treatment of chronic neck pain. BMJ. 2001;322(7302):1574–1578. https://doi.org/10.1136/bmj.322.7302.1574.

23. Hoving JL, de Vet HC, Koes BW, Mameren Hv, Devillé WL, van der Windt DA et al. Manual therapy, physical therapy, or continued care by the general practitioner for patients with neck pain: long-term results from a pragmatic randomized clinical trial. Clin J Pain. 2006;22(4):370–377. https://doi.org/10.1097/01.ajp.0000180185.79382.3f.

24. Devlikamova FI, Maksimov YuN, Khaibullina DKh. Comorbidity in back pain. Meditsinskiy Sovet. 2023;17(10):65–71. (In Russ.) https://doi.org/10.21518/ms2023-241.

25. Parfenov VA, Lamkova IA. Chronic musculoskeletal low back pain: comorbid disorders and therapy. Meditsinskiy Sovet. 2021;(10):34–41. (In Russ.) https://doi.org/10.21518/2079-701X-2021-10-34-41.

26. Alexeeva LI, Karateev AE, Popkova TV, Novikova DS, Sharapova EN, Markelova EP, Nasonov EL. Efficacy and safety of nimesulide long term administration in patients with osteoarthritis: results of 12-months open controlled study DINAMO (long term administration of nimesulide in osteoarthritis multifactor assessment). Rheumatology Science and Practice. 2009;47(4):64–72. (In Russ.) https://doi.org/10.14412/1995-4484-2009-1152.

27. Bunczak-Reeh MA, Hargreaves KM. Effect of inflammation on the delivery of drugs to dental pulp. J Endod. 1998;24(12):822–825. https://doi.org/10.1016/S0099-2399(98)80010-1.

28. Karateev AE. Nonsteroidal anti-inflammatory drugs in present-day clinical practice: pro more than con. Sovremennaya Revmatologiya. 2008;2(1):70–78. (In Russ.) https://doi.org/10.14412/1996-7012-2008-463.

29. Singla AK, Chawla M, Singh A. Nimesulide: some pharmaceutical and pharmacological aspects – an update. J Pharm Pharmacol. 2000;52(5):467–486. https://doi.org/10.1211/0022357001774255.

30. Rainsford KD. Nimesulide: overview of properties and applications. Drugs Today. 2001;37:3–7.

31. Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem. 2008;15(3):278–283. https://doi.org/10.2174/092986708783497247.

32. García-Nieto R, Pérez C, Checa A, Gago F. Molecular model of the interaction between nimesulide and human cyclooxygenase-2. Rheumatology (Oxford). 1999;38(1):14–18. https://doi.org/10.1093/rheumatology/38.suppl_1.14.

33. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res. 1997;46(11):437–446. https://doi.org/10.1007/s000110050221.

34. Bennett A, Villa G. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother. 2000;1(2):277–286. https://doi.org/10.1517/14656566.1.2.277.

35. Mukherjee P, Rachita C, Aisen PS, Pasinetti GM. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol. 2001;19(1):7–11. Available at: https://pubmed.ncbi.nlm.nih.gov/11296547.

36. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs. 1993;46(1):34–39. https://doi.org/10.2165/00003495199300461-00008.

37. Facino RM, Carini M, Aldini G. Antioxidant activity of nimesulide and its main metabolites. Drugs. 1993;46(1):15–21. https://doi.org/10.2165/00003495-199300461-00005.

38. Bianchi M, Broggini M, Balzarini P, Franchi S, Sacerdote P. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract. 2007;61(8):1270–1277. https://doi.org/10.1111/j.1742-1241.2007.01453.x.

39. Shah AA, Murray FE, Fitzgerald DJ. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology (Oxford). 1999;38(1):19–23. https://doi.org/10.1093/rheumatology/38.suppl_1.19.

40. Nasonov EL. Efficacy and tolerability of a non-steroidal anti-inflammatory drug. Nimesulide: new data. RMJ. 2001;(15):636. (In Russ.) Available at: https://www.rmj.ru/articles/revmatologiya/Effektivnosty_i_perenosimosty_nesteroidnogo_protivovospalitelynogo_preparata_Nimesulid_novye_dannye.